528 related articles for article (PubMed ID: 20722467)
1. Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer.
Guénard F; Pedneault CS; Ouellette G; Labrie Y; Simard J; ; Durocher F
Genet Test Mol Biomarkers; 2010 Aug; 14(4):515-26. PubMed ID: 20722467
[TBL] [Abstract][Full Text] [Related]
2. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
3. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
4. The contribution of founder mutations to early-onset breast cancer in French-Canadian women.
Ghadirian P; Robidoux A; Zhang P; Royer R; Akbari M; Zhang S; Fafard E; Costa M; Martin G; Potvin C; Patocskai E; Larouche N; Younan R; Nassif E; Giroux S; Narod SA; Rousseau F; Foulkes WD
Clin Genet; 2009 Nov; 76(5):421-6. PubMed ID: 19863560
[TBL] [Abstract][Full Text] [Related]
5. [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].
Pohlreich P; Kleibl Z; Kleiblová P; Janatová M; Soukupová J; Macháčková E; Házová J; Vašíčková P; Sťahlová Hrabincová E; Navrátilová M; Svoboda M; Foretová L
Klin Onkol; 2012; 25 Suppl():S59-66. PubMed ID: 22920209
[TBL] [Abstract][Full Text] [Related]
6. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J
Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019
[TBL] [Abstract][Full Text] [Related]
7. The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer.
Janatova M; Kleibl Z; Stribrna J; Panczak A; Vesela K; Zimovjanova M; Kleiblova P; Dundr P; Soukupova J; Pohlreich P
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2323-32. PubMed ID: 24136930
[TBL] [Abstract][Full Text] [Related]
8. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
9. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland.
Cybulski C; Lubiński J; Wokołorczyk D; Kuźniak W; Kashyap A; Sopik V; Huzarski T; Gronwald J; Byrski T; Szwiec M; Jakubowska A; Górski B; Dębniak T; Narod SA; Akbari MR
Clin Genet; 2015 Oct; 88(4):366-70. PubMed ID: 25330149
[TBL] [Abstract][Full Text] [Related]
10. Mutation analysis of PALB2 gene in French breast cancer families.
Damiola F; Schultz I; Barjhoux L; Sornin V; Dondon MG; Eon-Marchais S; Marcou M; ; Caron O; Gauthier-Villars M; de Pauw A; Luporsi E; Berthet P; Delnatte C; Bonadona V; Maugard C; Pujol P; Lasset C; Longy M; Bignon YJ; Fricker JP; Andrieu N; Sinilnikova OM; Stoppa-Lyonnet D; Mazoyer S; Muller D
Breast Cancer Res Treat; 2015 Dec; 154(3):463-71. PubMed ID: 26564480
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort.
McInerney NM; Miller N; Rowan A; Colleran G; Barclay E; Curran C; Kerin MJ; Tomlinson IP; Sawyer E
Breast Cancer Res Treat; 2010 May; 121(1):203-10. PubMed ID: 19763819
[TBL] [Abstract][Full Text] [Related]
12. The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2009 Apr; 114(3):457-62. PubMed ID: 18446436
[TBL] [Abstract][Full Text] [Related]
13. PALB2 mutations 1592delT and 229delT are not present in Korean breast cancer patients negative for BRCA1 and BRCA2 mutations.
Kim JH; Choi DH; Cho DY; Ahn SH; Son BH; Haffty BG
Breast Cancer Res Treat; 2010 Jul; 122(1):303-6. PubMed ID: 20213081
[TBL] [Abstract][Full Text] [Related]
14. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.
Wong MW; Nordfors C; Mossman D; Pecenpetelovska G; Avery-Kiejda KA; Talseth-Palmer B; Bowden NA; Scott RJ
Breast Cancer Res Treat; 2011 Jun; 127(3):853-9. PubMed ID: 21409391
[TBL] [Abstract][Full Text] [Related]
15. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
Tonin PN
Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
[TBL] [Abstract][Full Text] [Related]
16. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
Meijers-Heijboer H; van den Ouweland A; Klijn J; Wasielewski M; de Snoo A; Oldenburg R; Hollestelle A; Houben M; Crepin E; van Veghel-Plandsoen M; Elstrodt F; van Duijn C; Bartels C; Meijers C; Schutte M; McGuffog L; Thompson D; Easton D; Sodha N; Seal S; Barfoot R; Mangion J; Chang-Claude J; Eccles D; Eeles R; Evans DG; Houlston R; Murday V; Narod S; Peretz T; Peto J; Phelan C; Zhang HX; Szabo C; Devilee P; Goldgar D; Futreal PA; Nathanson KL; Weber B; Rahman N; Stratton MR;
Nat Genet; 2002 May; 31(1):55-9. PubMed ID: 11967536
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive sequencing of PALB2 in patients with breast cancer suggests PALB2 mutations explain a subset of hereditary breast cancer.
Fernandes PH; Saam J; Peterson J; Hughes E; Kaldate R; Cummings S; Theisen A; Chen S; Trost J; Roa BB
Cancer; 2014 Apr; 120(7):963-7. PubMed ID: 24415441
[TBL] [Abstract][Full Text] [Related]
18. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.
Falchetti M; Lupi R; Rizzolo P; Ceccarelli K; Zanna I; Calò V; Tommasi S; Masala G; Paradiso A; Gulino A; Giannini G; Russo A; Palli D; Ottini L
Breast Cancer Res Treat; 2008 Jul; 110(1):161-7. PubMed ID: 17661168
[TBL] [Abstract][Full Text] [Related]
19. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
[TBL] [Abstract][Full Text] [Related]
20. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB
BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
